classifying xylazine as a schedule III controlled drug.

Introduced

In Committee

Floor

Crossed Over

Passed

Enacted

Overview Bill text 2 Compare versions History 12 Sponsors 10

No summary has been published for this bill. The full text is on the Bill text tab.

Chamber: Senate
Introduced: Nov 21, 2025
Last action: Apr 15, 2026 — Majority Committee Report: Inexpedient to Legislate 04/14/2026 (Vote 11-5; RC)
Sponsor: Bill Gannon R
Session: 2026
Momentum: 5 · Stalled